Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified

West Pharmaceutical Services

(

WST

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified West Pharmaceutical Services as such a stock due to the following factors:

  • WST has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.0 million.
  • WST has traded 186,952 shares today.
  • WST is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in WST with the Ticky from Trade-Ideas. See the FREE profile for WST NOW at Trade-Ideas

More details on WST:

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.8%. WST has a PE ratio of 31.3. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for West Pharmaceutical Services has been 251,800 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.4 billion and is part of the health care sector and health services industry. The stock has a beta of 0.82 and a short float of 2.2% with 6.02 days to cover. Shares are up 78.9% year to date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates West Pharmaceutical Services as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 5.3%. Since the same quarter one year prior, revenues rose by 12.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • WEST PHARMACEUTICAL SVSC INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, WEST PHARMACEUTICAL SVSC INC increased its bottom line by earning $1.15 versus $1.08 in the prior year. This year, the market expects an improvement in earnings ($1.62 versus $1.15).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 81.1% when compared to the same quarter one year prior, rising from $14.80 million to $26.80 million.
  • Net operating cash flow has slightly increased to $53.30 million or 3.29% when compared to the same quarter last year. In addition, WEST PHARMACEUTICAL SVSC INC has also vastly surpassed the industry average cash flow growth rate of -56.10%.
  • 37.27% is the gross profit margin for WEST PHARMACEUTICAL SVSC INC which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 7.84% trails the industry average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null